One-carbon therapeutics AB is discussing the ODIN trial with several leading clinical sites at the upcoming ESMO meeting in Barcelona. The ODIN trial is a first-in-human, first-in-class clinical phase 1/2 trial with MTHFD1/2 inhibitor TH9619 in selected solid cancers.
One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million)
Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage
